The Medicines Management Programme has Managed Access Protocols in place for a number of medicines as part of the reimbursement approval process.

This section contains information on medicines that are subject to Managed Access Protocols. Reimbursement criteria for each medicine are individual. Please refer to the relevant link for information on individual Managed Access Protocols:

• Bempedoic Acid
• Berotralstat (Orladeyo®)
• CGRP MABs
• Cibinqo®, Dupixent®, Adtralza®, RINVOQ®
• Eculizumab (Soliris®)
• Entrectinib (Rozlytrek®) - Lung Cancer
• Entrectinib (Rozlytrek®) - NTRK gene fusion
• Fostemsavir (Rukobia®)
• Inotersen (Tegsedi®)
• Lanadelumab (Takhzyro®)
• Larotrectinib (Vitrakvi®)
• Lidocaine (Versatis®)
• Liraglutide (Saxenda®)
• Nusinersen (Spinraza®)
• Obeticholic acid (Ocaliva®)
• Odevixibat (Bylvay®)
• Onasemnogene abeparvovec (Zolgensma®)
• Patisiran (Onpattro®)
• PCSK9 Inhibitors
• Risdiplam (Evrysdi®)
• Rivaroxaban 2.5mg
• Romosozumab (Evenity®)
• Sacubitril & Valsartan-(Entresto®)
• Severe Asthma – Dupilumab (Dupixent®)
• Tafamidis (Vyndaqel®)
• Teduglutide (Revestive®)
• THC/CBD (Sativex®)
• Tolvaptan (Jinarc®)
• Voretigene neparvovec (Luxturna®)
• Vutrisiran (Amvuttra®)